Southern California Cellular Research Company Announces Publication of "Human Prenatal Intestine Cells as a Valuable Source of Stem Cells and Epithelial Cells: Phenotypic and Functional Characterizati

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Southern California Cellular Research Company Announces Publication of "Human Prenatal Intestine Cells as a Valuable Source of Stem Cells and Epithelial Cells: Phenotypic and Functional Characterization" in the Scientific Journal CELL & TISSUE TRANSPLANTATION & THERAPY


Southern California Cellular Research Company Announces Publication of "Human Prenatal Intestine Cells as a Valuable Source of Stem Cells and Epithelial Cells: Phenotypic and Functional Characterization" in the Scientific Journal CELL & TISSUE TRANSPLANTATION & THERAPY

PR Newswire

COSTA MESA, Calif., May 29, 2014 /PRNewswire/ -- DaVinci Biosciences, LLC announced today that their paper on "Human Prenatal Intestine Cells as a Valuable Source of Stem Cells and Epithelial Cells; Phenotypic and Functional Characterization" has been accepted for publication in the peer-reviewed journal CELL & TISSUE TRANSPLANTATION & THERAPY.

With the current move by researchers and governments to reduce the use of animals in drug development and testing, scientists are looking for better and more cost effective ways to conduct their research for new and novel drugs for human disease. DaVinci Biosciences recognizes the need for new methods and models that will help get compounds from the bench top to clinical trials and has been continuously working to isolate and develop human primary cells for this purpose.

DaVinci Biosciences continues to research and develop cellular biology models that will promote the use of responsible science for the development and implementation of new approaches in the discovery of new therapeutic therapies. "It is a pleasure to work with DV Biologics in developing new cell based models for research and drug development. Our goal is to find more realistic models that may mimic the in vivo system," says Dr. Rafael Gonzalez, VP of Research and Development of DaVinci Biosciences.  "It is our belief that these cell models will enable researchers to reduce the amount of animals used in drug discovery while getting faster results in the compounds safety and efficacy," says Tony Delamaza, Vice President of Sales of DaVinci Biosciences.

About DaVinci Biosciences
DaVinci Biosciences is a leading global research and development company of human primary cells, cell derived product, and processes. DaVinci Biosciences distributes its cells and licenses its patents through its sister company DV Biologics.

About DV Biologics LLC
DV Biologics is a leading global supplier of human primary cells and cell-derived products.  DV Biologics manufactures the highest quality biological tools for use in academic institutions and pharmaceutical laboratories engaging in cell and drug based discovery and development. DV Biologics offers normal, human-derived primary cells and cell lines for research, genomic and proteomic biological tools, and a line of disease-specific primary cells and cell lines for the most accurate study of a particular disease profile.  All of DV Biologics' products are validated under the strictest quality assurance and control parameters, providing customers with reliable, guaranteed quality products for reproducible results.

DaVinci Biosciences and DV Biologics are headquartered in Costa Mesa, California.

SOURCE DaVinci Biosciences, LLC

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here